Exhibit 99.1 Press Release Regeneron Reports First Quarter 2024 Financial and Operating Results • First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7% • First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023 • First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HD • First quarter 2024 Libtayo® glob ...

Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report first-quarter results on May 2, 2024.Once a rock-solid biotech stock to invest in, Regeneron is currently facing challenges for its lead drug, Eylea, which is its primary growth engine.  These challenges are likely to have negatively impacted the upcoming results.The Zacks Consensus Estimate for REGN’s first-quarter revenues is pegged at $3.2 billion, while the same for earnings is pinned at $10.20 per share.Decline in Eylea SalesA sig ...

A downtrend has been apparent in Regeneron (REGN) lately with too much selling pressure. The stock has declined 8.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for sp ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $10.14 per share, indicating an increase of 0.5% compared to the year-ago period. Analysts forecast revenues of $3.19 billion, representing an increase of 0.8% year over year.The consensus EPS estimate for the quarter has been revised 2.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to ...

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA® HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA® (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle. "Our extensive dat ...

Mammoth's proprietary ultracompact CRISPR-based gene editing platform and Regeneron's proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and commercialize in vivo CRISPR-based gen ...

Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene ...

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). The investigation concerns whether Regeneron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On April 10, 2024, the U.S. Department of Justice ("DOJ") issued a press release announci ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Regeneron (REGN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This biopharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 10.51%.For the most recent quarter, Regeneron was expected to p ...

Shares of Regeneron Pharmaceuticals (REGN) were down 1.70% on Apr 11, following a complaint filed by the U.S. Department of Justice against the company, alleging fraudulent drug pricing practices related to its lead drug, Eylea.The Department filed a complaint under the False Claims Act (FCA) against Regeneron, which manufactures and sells the ophthalmology drug, Eylea. The lawsuit was originally filed under the qui tam or whistleblower provisions of the FCA.Eylea is an anti-vascular endothelial growth fact ...